

Agri Inputs | Q4FY23 Result Update

- Dhanuka Agritech reported a revenue growth of 16.6% YoY to Rs 3.7bn (D.est: Rs 3.6bn) with equal growth witnessed in both pricing and volumes.
- EBITDA grew by 19.7% YoY to Rs 779mn (D.est : Rs 649mn) which was led by lower employee costs (up 4% YoY) and lower Opex (down 3% YoY) translating to an EBITDA margin improvement of 53bps YoY to 21%
- PAT grew by 20.3% YoY to Rs 653mn (D.est : Rs 541mn) driven by healthy operational performance.

Double digit growth guidance maintained despite near term uncertainties

Agrochem industry is currently facing a downturn owing to high channel inventory situation and destocking by customers. Despite these current challenges the management is confident of delivering a double digit growth in FY24 which should be largely driven by volumes gains. Gross margins are also expected to inch upwards going forward which shall translate into improvement in EBITDA margins as well.

Investment in Technical manufacturing to drive growth in the long term

Company is expected to commence commercial production from its new technical plant from mid of July 23 with introduction of Bifenthrin Technical. Company's idea behind foraying into technicals is to showcase its capabilities of manufacturing technical grade pesticides and secure supply contract from Japanese Innovator companies for production of specialty molecules. Successful tie ups with Japanese partners shall open door for the company to tap into the large contract manufacturing space and will lead to solid growth both in terms of revenues and margins in the long run.

Outlook and Valuation

We have revised our EPS estimates upwards by 7.9/9.5% for FY24E/FY25E respectively taking into account the healthy Q4FY23 performance and positive management guidance. We however remain cautious of the weaker monsoon forecast which could have a negative bearing on FY24 performance and thus expect growth to be at the lower range of the guidance. Company has recently added 5 new products which includes 3 products in the biologicals category where the company foresees a large opportunity. We remain optimistic of the company's long term growth prospects led by foray into technicals and focus on new product introductions. We maintain our BUY rating with a revised target price of Rs 985 (17x FY25E EPS).

Q4FY23 Result (Rs Mn)

Particulars	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)
Revenue	3,712	3,183	16.6	3,934	(5.6)
Total Expense	2,934	2,532	15.9	3,415	(14.1)
EBITDA	779	651	19.7	518	50.3
Depreciation	51	45	14.7	45	14.5
EBIT	728	606	20.0	474	53.6
Other Income	147	122	20.9	77	92.4
Interest	8	8	0.8	8	(1.0)
EBT	867	721	20.4	543	59.9
Tax	214	178	20.6	82	161.6
RPAT	653	543	20.3	461	41.8
APAT	653	543	20.3	461	41.8
			(bps)		(bps)
Gross Margin (%)	38.2	40.5	(236)	32.9	527
EBITDA Margin (%)	21.0	20.4	53	13.2	780
NPM (%)	17.6	17.1	54	11.7	588
Tax Rate (%)	24.7	24.7	5	15.1	961
EBIT Margin (%)	19.6	19.0	55	12.0	756

CMP	Rs 720
Target / Upside	Rs 985 / 37%
NIFTY	18,321

Scrip Details

Equity / FV	Rs 91mn / Rs 2		
Market Cap	Rs 33bn		
	USD 399.6mn		
52-week High/Low	Rs 750/ 605		
Avg. Volume (no)	18,559		
Bloom Code	DAGRI IN		
Price Performance	1M	3M	12M
Absolute (%)	13	8	2
Rel to NIFTY (%)	10	3	(14)

Shareholding Pattern

	Sep'22	Dec'22	Mar'23
Promoters	70.0	70.2	70.2
MF/Banks/FIs	16.6	16.7	16.7
FIIIs	4.0	4.0	4.0
Public / Others	9.4	9.2	9.2

Valuation (x)

	FY23P	FY24E	FY25E
P/E	87.3	13.3	12.2
EV/EBITDA	38.5	10.0	8.4
ROE (%)	3.7	21.2	19.6
RoACE (%)	3.8	20.6	19.2

Estimates (Rs bn)

	FY23P	FY24E	FY25E
Revenue	17.0	18.7	20.9
EBITDA	0.8	3.2	3.6
PAT	0.4	2.5	2.7
EPS (Rs.)	8.3	54.1	59.2

Analyst: Tejas Sonawane

Tel: +91 22 40969792

E-mail: tejass@dolatcapital.com

Exhibit 1: Actual vs Estimates

Particulars (Rs Mn)	Actual	Estimated	Variance %	Comments
Revenue	3,712	3,550	4.6	In-line
EBITDA	779	649	20.0	Lower than expected Opex and
EBITDA Margin (%)	21.0	18.3	269bps	employee costs.
PAT	653	541	20.7	Better than expected operational performance.

Source: DART

Exhibit 2: Change in estimates

(Particulars (Rs Mn))	FY24E			FY25E		
	New	Previous	Chg. (%)	New	Previous	Chg. (%)
Revenue	18,702	18,190	2.8	20,947	19,646	6.6
EBITDA	3,160	2,995	5.5	3,598	3,349	7.4
EBITDA Margin(%)	16.9	16.5	43bps	17.2	17	13bps
PAT	2,468	2,288	7.9	2,700	2,465	9.5
EPS(Rs)	53.0	49.1	7.9	58.0	52.9	9.5

Source: DART

We have revised our FY24E/FY25E estimates taking into account the healthy Q4FY23 numbers and positive growth guidance provided by the management.

Earning call KTAs
Category Wise revenue mix Q4FY23

- Insecticides – 46%
- Fungicides – 17%
- Herbicides – 26%
- Others – 11%

Region Wise revenue Mix Q4FY23

- North – 29%
- South – 41%
- East – 11%
- West – 19%

Pricing Environment

- Raw material prices are currently on a declining trend with fall in crude oil prices.
- Commodity prices continue to remain at elevated levels with positive trend witnessed in Wheat and Sugarcane.
- With moderation in raw material prices end product prices are also witnessing a downtick.

Technical Plant at Dahej

- Commercial production is expected to start from 3rd week of July with manufacture of Bifenthrin technical.
- Company will use divert some volumes of this product towards captive use with balance expected to be sold outside equally in the domestic and export market.
- Expects to generate ~Rs 500mn in sales in FY24 at a gross margin of ~20%.
- Synthetic Pyrethroids market is currently witnessing significant pricing pressure.

- However Bifenthrin situation remain favorable and company expects positive contribution from this product going forward.

Strengthening of relationship with Channel partners

- Company expanded its reach towards both primary and secondary channel partners.
- Primary channel includes companys direct accounts while the secondary channel consists of sub retailers.

Channel Inventory


- Management indicated that the channel inventory situation remains mixed rabi inventory still in the pipeline.
- Products towards Maize, Sugarcane, Paddy and Soybean are seeing a good traction.
- Company has liquidated majority of its high cost inventory in Q4FY23 with some carry over seen in Q1FY24.

Export business for Formulations


- Expected to see good growth over next 2-3 years.
- Company is receiving good response with international customers.
- Currently will be aiming to target easy to reach non regulated markets with ultimate goal to enter into regulated regions.

Other Highlights


- Q4FY23 revenue growth was led by equal jump in volumes and prices.
- FY23 revenue growth was a function of 8% volume increase and balance from pricing gains.
- Company has in recent times introduced products towards arid and dry applications which would mitigate the risk of lower rainfall.
- Going forward company will continue to increase its presence in Insecticides segment and expects share of Insecticides to move up.
- Contribution of Biologicals to overall sales is expected to reach ~5% over next 3 years.

Exhibit 3: Consolidated Revenues vs EBITDA Margin



Source: DART

Exhibit 4: Geography Wise Revenue Breakup (Q4FY23)


Source: DART

Exhibit 5: Segment Wise Revenue Breakup (Q4FY23)


Source: DART

Exhibit 6: Innovation Turnover Index (ITI) (New molecules as a % of total revenue)


Source: DART

Financial Performance

Profit and Loss Account

(Rs Mn)	FY22A	FY23P	FY24E	FY25E
Revenue	14,778	17,002	18,702	20,947
Total Expense	12,144	16,174	15,542	17,349
COGS	9,391	13,113	12,110	13,458
Employees Cost	1,205	1,263	1,414	1,570
Other expenses	1,548	1,798	2,018	2,321
EBIDTA	2,634	828	3,160	3,598
Depreciation	163	176	279	410
EBIT	2,471	652	2,882	3,187
Interest	32	31	40	45
Other Income	336	448	457	466
Exc. / E.O. items	0	0	0	0
EBT	2,775	1,068	3,298	3,608
Tax	687	692	830	908
RPAT	2,088	376	2,468	2,700
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	2,088	376	2,468	2,700

Balance Sheet

(Rs Mn)	FY22A	FY23P	FY24E	FY25E
Sources of Funds				
Equity Capital	93	91	91	91
Minority Interest	0	0	0	0
Reserves & Surplus	9,511	10,522	12,625	14,778
Net Worth	9,604	10,613	12,716	14,869
Total Debt	10	38	38	38
Net Deferred Tax Liability	474	461	461	461
Total Capital Employed	10,088	11,112	13,215	15,368

Applications of Funds

Net Block	1,587	1,646	3,900	4,590
CWIP	483	1,532	700	150
Investments	1,505	1,913	1,913	1,913
Current Assets, Loans & Advances	9,547	8,962	9,886	12,224
Inventories	3,472	3,451	3,796	4,251
Receivables	2,825	3,390	3,729	4,177
Cash and Bank Balances	24	43	283	1,718
Loans and Advances	364	674	674	674
Other Current Assets	901	446	446	446
Less: Current Liabilities & Provisions	3,034	2,941	3,184	3,508
Payables	1,747	1,752	1,876	2,044
Other Current Liabilities	1,287	1,189	1,308	1,464
<i>sub total</i>				
Net Current Assets	6,513	6,020	6,702	8,715
Total Assets	10,088	11,112	13,215	15,368

E – Estimates

Important Ratios

Particulars	FY22A	FY23P	FY24E	FY25E
(A) Margins (%)				
Gross Profit Margin	36.5	22.9	35.3	35.8
EBIDTA Margin	17.8	4.9	16.9	17.2
EBIT Margin	16.7	3.8	15.4	15.2
Tax rate	24.8	64.8	25.2	25.2
Net Profit Margin	14.1	2.2	13.2	12.9
(B) As Percentage of Net Sales (%)				
COGS	63.5	77.1	64.8	64.3
Employee	8.2	7.4	7.6	7.5
Other	10.5	10.6	10.8	11.1
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	77.2	20.9	72.0	70.8
Inventory days	86	74	74	74
Debtors days	70	73	73	73
Average Cost of Debt	68.7	130.7	105.0	118.2
Payable days	43	38	37	36
Working Capital days	161	129	131	152
FA T/O	9.3	10.3	4.8	4.6
(D) Measures of Investment				
AEPS (Rs)	45.8	8.3	54.1	59.2
CEPS (Rs)	49.4	12.1	60.3	68.2
DPS (Rs)	14.3	6.0	8.0	0.0
Dividend Payout (%)	31.2	72.7	14.8	0.0
BVPS (Rs)	210.7	232.9	279.0	326.2
RoANW (%)	23.8	3.7	21.2	19.6
RoACE (%)	22.6	3.8	20.6	19.2
RoAIC (%)	26.4	6.2	24.0	24.0
(E) Valuation Ratios				
CMP (Rs)	720	720	720	720
P/E	15.7	87.3	13.3	12.2
Mcap (Rs Mn)	32,837	32,837	32,837	32,837
MCap/ Sales	2.2	1.9	1.8	1.6
EV	30,862	31,874	31,634	30,199
EV/Sales	2.1	1.9	1.7	1.4
EV/EBITDA	11.7	38.5	10.0	8.4
P/BV	3.4	3.1	2.6	2.2
Dividend Yield (%)	2.0	0.8	1.1	0.0
(F) Growth Rate (%)				
Revenue	6.5	15.1	10.0	12.0
EBITDA	(2.1)	(68.6)	281.6	13.8
EBIT	(2.7)	(73.6)	341.9	10.6
PBT	(2.6)	(61.5)	208.7	9.4
APAT	(0.8)	(82.0)	556.0	9.4
EPS	(0.8)	(82.0)	556.0	9.4

E – Estimates

Cash Flow

Particulars	FY22A	FY23P	FY24E	FY25E
Profit before tax	2,775	3,027	3,298	3,608
Depreciation & w.o.	163	176	279	410
Net Interest Exp	32	31	40	45
Direct taxes paid	(714)	(724)	(830)	(908)
Change in Working Capital	(534)	(694)	(441)	(579)
Non Cash	0	0	0	0
(A) CF from Operating Activities	1,721	1,816	2,345	2,577
Capex {(Inc.)/ Dec. in Fixed Assets n WIP}	(488)	248	(1,700)	(1,100)
Free Cash Flow	1,233	2,064	645	1,477
(Inc.)/ Dec. in Investments	(579)	812	0	0
Other	(11)	11	0	0
(B) CF from Investing Activities	(1,078)	1,071	(1,700)	(1,100)
Issue of Equity/ Preference	0	(2)	0	0
Inc./(Dec.) in Debt	(74)	28	0	0
Interest exp net	(32)	(31)	(40)	(45)
Dividend Paid (Incl. Tax)	(466)	(273)	(365)	(547)
Other	(62)	(1,059)	0	0
(C) CF from Financing	(634)	(1,337)	(405)	(592)
Net Change in Cash	9	1,551	240	885
Opening Cash balances	15	24	43	283
Closing Cash balances	24	1,575	283	1,168

E – Estimates


Notes

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Aug-22	BUY	1,026	697
Feb-23	BUY	900	669

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
-------------	-------------------	-------------------------	-----------------

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
-------------------	------------------	-----------------------	-----------------

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Girish Raj Sankunny	VP - Equity Sales	girishr@dolatcapital.com	+9122 4096 9625
Pratik Shroff	AVP - Equity Sales	pratiks@dolatcapital.com	+9122 4096 9621
Equity Trading	Designation	E-mail	Direct Lines
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Naman Midtown, A-1203, 12th Floor, Senapati Bapat Marg, Prabhadevi, Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990GJ993PTC116741

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000000685

Regd. office: 1401-1409, Dalal Street Commercial, Block 53 (Bldg. No.53E) Zone-5, Road-5E, Gift City, Sector 9, Gandhinagar-382355 Gujarat, India.

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com
